[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"gastric-cancers\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:gastric-cancers":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,55,80,102,130,152,175,200,247],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":54},"100609796","phase-2-study-to-evaluate-the-diagnostic-performance-of-geh300079-68ga-injection-petct-for-detection-of-pc-in-patients-with-colorectal-gastric-ovarian-or-pancreatic-cancers-periscope-100609796",false,"NCT07219238","Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET\u002FCT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)","A Phase 2\u002F3, Multicenter, Open-Label, Non-Randomized Study to Evaluate Diagnostic Performance of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)\u002FComputed Tomography (CT) for Detection of Peritoneal Carcinomatosis (PC) in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)","Inclusion Criteria:\n\n* Participant is ≥18 years of age\n* Participant has provided signed informed consent before any study-specific screening procedures\n* Participant has histopathologically confirmed primary colorectal, gastric or ovarian cancer or PDAC\n* Participant has known or suspected PC from the tumor of origin. Suspicion may be based on imaging or clinical findings.\n* Participant is scheduled for peritoneal surgery with curative intent, surgical exploration, or laparoscopy, with either: a. No neoadjuvant treatment received, treatment-naïve (i.e., undergoing upfront surgery or laparoscopy) b. Completed systemic treatment (which may include neoadjuvant chemotherapy) before GEH300079 ( 68Ga) PET\u002FCT Imaging Visit\n* Participant has Eastern Cooperative Oncology Group (ECOG) performance status ≤2\n* Participant is able and willing to comply with all study procedures as described in the protocol\n\nExclusion Criteria:\n\n* Participant is pregnant or breast-feeding, or sexually active and not using or not willing to use an acceptable form of birth control from screening up to 30 days after receiving the investigational medicinal product (IMP)\n* Participant has a known disorder that, in the opinion of the investigator, will impact the study procedures\n* Participant needs any intervention that would delay study participation\n* Participant has non-resectable extra-abdominal metastasis and\u002For \\>3 hepatic metastases on standard work up\n* Participant will not be able to complete the study, based on their anticipated life expectancy\n* Participant has active bacterial, viral, or fungal infection requiring systemic antibacterial, anti-viral or antifungal therapy (topical medications are permitted)\n* Participant has renal function impairment as defined by:\n\n  1. For Phase 2: estimated glomerular filtration rate less than 60 mL\u002Fmin\n  2. For Phase 3: estimated glomerular filtration rate less than 30 mL\u002Fmin\n* Participant has severe hepatic function impairment as defined by:\n\n  1. Aspartate aminotransferase (serum glutamic-oxaloacetic transaminase) and alanine aminotransferase (serum glutamic-pyruvic transaminase): ≤2.5 × upper limit of normal (ULN; ≤5 × ULN for participants with liver metastases)\n  2. Bilirubin: ≤1.5 × ULN or direct bilirubin ≤ULN for participants with total bilirubin levels \\>1.5 × ULN\n* Participant has autoimmune disease that required systemic treatment in the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid) is allowed\n* Participant has serious co-morbidities or serious non-malignant disease that in the opinion of the investigator, could compromise participant safety and\u002For protocol objectives\n* Participant either received or is planning to receive any other investigational agent within the 28 days prior to the first imaging visit or during study participation (with the exception of the 3-month follow-up period)\n* Participant has known or suspected hypersensitivity to any excipients used in GEH300079 (68Ga)\n* Participant has severe claustrophobia, is unable to lie flat or fit into the scanner, or is unable to tolerate the PET\u002FCT scan for any reason\n* (Phase 3 only) Participant was previously included in Phase 2 of this study","ALL","18 Years",{"count":19,"type":20},175,"ESTIMATED","INTERVENTIONAL",[23,24],"PHASE2","PHASE3","This study is a Phase 2\u002F3, prospective, multicenter, open-label, non-randomized clinical trial, in which GEH300079 (68Ga) PET\u002FCT images will be acquired in patients with primary colorectal, gastric, ovarian, or Pancreatic Ductal Adenocarcinoma (PDAC) cancers and known or suspected Peritoneal Carcinomatosis (PC) before or after institutional Standard of Care (SoC) imaging. The primary objective is to evaluate the diagnostic performance of GEH300079 (68Ga) PET\u002FCT for the detection of PC in patients with colorectal, gastric, or ovarian primary cancers, using a composite standard of truth (SoT), in a region-based analysis. The detection of PC in patients with primary PDAC will be explored in the Phase 2 part of the study.\n\nThe study is comprised of 2 distinct parts: Phase 2 aims to confirm the statistical and scientific assumptions for the Phase 3 part, and to confirm the optimal dose and timing of acquisition of GEH300079 (68Ga) PET\u002FCT in the PC indication. Phase 2 includes 2 cohorts: Cohort A (participants with colorectal, ovarian and gastric primary cancer), and Cohort B (participants with primary PDAC), where analysis of Cohort B is descriptive only. Phase 3 aims to demonstrate the safety and efficacy of GEH300079 (68Ga) PET\u002FCT for the detection of PC in patients with confirmed colorectal, gastric or ovarian primary cancers.",[27,28,29,30],"Colorectal Cancer","Gastric Cancers","Ovarian Cancers","Pancreatic Ductal Adenocarcinoma",[32,33,34,35,36,37,38,39,40,41],"Peritoneal Carcinomatosis (PC)","Pancreatic Cancers","Colorectal cancer","Gastric cancer","FAPI","Ovarian cancer","68Ga","PET\u002FCT imaging","Diagnostic imaging","Diagnostic performance","RECRUITING","2026-06-16",{"date":45,"type":46},"2026-06-17","ACTUAL",{"date":48,"type":20},"2026-10",{"date":50,"type":20},"2029-08",{"name":52,"class":53},"GE Healthcare","INDUSTRY",2,{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":4,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":21,"phases":64,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":70,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100394880","phase-1-bold-100-in-combination-with-folfox-for-the-treatment-of-advanced-solid-tumours-100394880","NCT04421820","BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours","A Phase 1b\u002F2a Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours","Inclusion Criteria:\n\n1. Be 18 years or older.\n2. Be male or non-pregnant females who agree to comply with applicable contraceptive requirements of the protocol.\n3. Histologically and\u002For cytologically confirmed gastrointestinal tumours that are metastatic or unresectable. (ARM VII): Patients must have received only 1 prior line of therapy in the metastatic setting.\n4. Have measurable disease according to RECIST v1.1.\n5. Have an anticipated survival of at least 16 weeks.\n6. Be ambulatory, with an ECOG performance score of 0 or 1.\n7. Have adequate organ function.\n8. Be on stable doses of any drugs that may affect hepatic drug metabolism or renal drug excretion.\n9. Be fully informed about their illness and the investigational nature of the study protocol, and sign a REB-approved Informed Consent Form (ICF).\n10. (ARM VII): BRAF wild-type tumour status.\n\nExclusion Criteria:\n\n1. Neuropathy \\> grade 2\n2. Previous intolerance to or significant reaction secondary to fluorouracil or oxaliplatin.\n3. Cerebrovascular accident within the past 6 months before the start of treatment.\n4. History or presence of central nervous system (CNS) metastasis or leptomeningeal tumours.\n5. Any serious medical conditions that might be aggravated by treatment or limit compliance.\n6. Any history of serious cardiac illness.\n7. Hemoptysis, cerebral, or clinically significant gastrointestinal hemorrhage in the past 6 months before the start of treatment.\n8. Any other known malignancy within 3 years before the start of treatment.\n9. Active gastrointestinal tract disease with malabsorption syndrome.\n10. Non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease.\n11. Treatment with radiation therapy or surgery within 4 weeks prior to starting treatment.\n12. Recent history of weight loss \\> 10% of current body weight in past 3 months before the start of treatment.\n13. HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.\n14. Concurrent use of another investigational therapy or anti-cancer therapy within 4 weeks before the start of treatment.\n15. Currently breastfeeding\n16. Dihydropyrimidine Dehydrogenase (DPD) deficiency\n17. Current or prior treatment with potent inhibitors of Dihydropyrimidine Dehydrogenase (DPD)\n18. (ARM VII): Prior exposure to BOLD-100\n19. (ARM VII): Subjects with microsatellite-high (MSI-H) Tumours\n20. (ARM VII): Concurrent monoclonal antibody therapy for mCRC (anti-EGFR, anti-VEGF or anti-HER2)",{"count":63,"type":20},220,[65,23],"PHASE1","BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.",[27,68,28,69],"Pancreatic Cancer","Cholangiocarcinoma","2026-05-15",{"date":72,"type":46},"2026-05-18",{"date":74,"type":46},"2020-08-28",{"date":76,"type":20},"2026-09-01",{"name":78,"class":53},"Bold Therapeutics, Inc.",24,{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":89,"conditions":90,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":101},"100164675","tissue-procurement-for-gastric-cancer-gastrointestinal-stromal-tumors-gist-esophageal-cancer-pancreas-cancer-hepatocellular-cancer-biliary-cancer-neuroendocrine-peritoneal-mesothelioma-anal-cancer-and-colorectal-cancer-in-patients-undergoing-surgery-or-biopsy-100164675","NCT01416714","Tissue Procurement for Gastric Cancer, Gastrointestinal Stromal Tumors (GIST), Esophageal Cancer, Pancreas Cancer, Hepatocellular Cancer, Biliary Cancer, Neuroendocrine, Peritoneal Mesothelioma, Anal Cancer and Colorectal Cancer in Patients Undergoing Surgery or Biopsy","Inclusion Criteria:\n\n* any patient diagnosed with Gastric (stomach) Cancer, Esophageal (foodpipe) Cancer, Pancreas Cancer, Liver Cancer, Biliary (gallbladder) Cancer, Gastrointestinal Stromal Tumor, Peritoneal Mesothelioma (cancer in the lining of the abdomen), Neuroendocrine (of or relating to the cells that release a hormone into the blood in response to a neural stimulus) Tumor, Anal Cancer or Colorectal Cancer cancer that requires you to undergo a surgical or diagnostic procedure.",{"count":87,"type":20},1000,"OBSERVATIONAL","The purpose of this study is to collect and store normal and malignant tissue from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer and colorectal cancer, an estimated 50 to 100 of each tumor type. To collect and store blood samples from patients with gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer and colorectal cancer. To create a database for the collected tissue and allow access to relevant clinical information for current and future protocols. To create tissue microarrays for each gastrointestinal cancer subtype, namely, gastric cancer, GIST, esophageal cancer, pancreas cancer, hepatocellular cancer, biliary cancer, neuroendocrine, peritoneal mesothelioma, anal cancer and colorectal cancer, to facilitate future molecular studies. To grant access to Dr Kindler, Dr. Salgia, and Dr. Catenacci to this database (as it is being acquired) of the coupled patient tissue samples (normal and malignant) and relevant clinical information for the investigation of tyrosine kinases, such as Met and Ron, receptor tyrosine kinase family members, STATs, paxillin, focal adhesion proteins, cell motility\u002Fmigration proteins, tyrosine\u002Fserine\u002Fthreonine kinase family members, related molecules, and downstream targets implicated in the pathogenesis of GI cancers. Examples of molecular testing include evaluation of DNA mutation, alternative splice variants, protein expression and phosphorylation, and immunohistochemistry on samples. These studies will be correlated with clinical information as stated above.",[28],"2025-09-29",{"date":93,"type":46},"2025-10-01",{"date":95,"type":46},"2008-07-02",{"date":97,"type":20},"2030-01",{"name":99,"class":100},"University of Chicago","OTHER",1,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":110,"enrollmentInfo":111,"targetDuration":113,"studyType":88,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":101},"100572100","analysis-of-lymph-node-metastasis-and-tumor-deposit-in-the-short-gastric-mesentery-following-total-gastrectomy-for-gastric-cancer-100572100","NCT06728878","Analysis of Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy for Gastric Cancer","Lymph Node Metastasis and Tumor Deposit in the Short Gastric Mesentery Following Total Gastrectomy With D2 Lymphadenectomy Plus Complete Mesogastric Excision for Gastric Cancer: A Prospective Observational Study","zytg001","Inclusion Criteria:\n\n1. Aged older than 18 years and younger than 85 years\n2. Primary gastric adenocarcinoma confirmed by preoperative pathology result\n3. cT2-4aN0-3M0 at preoperative evaluation according to the American Joint 8 Committee on Cancer (AJCC) Cancer Staging Manual 8th Edition\n4. Patients who received total gastrectomy with D2 lymphadenectomy plus complete mesogastric excision\n5. American Society of Anesthesiologists (ASA) class I, II, or III\n6. Written informed consent\n\nExclusion Criteria:\n\n1. Negative preoperative biopsy\n2. Too late tumour stage or metastasis (cT4b\u002FM1)\n3. BMI\\>30 kg\u002Fm2\n4. previous neoadjuvant chemotherapy or radiotherapy\n5. Previous upper abdominal surgery\n6. Combined with other malignant diseases\n7. Reject operation","85 Years",{"count":112,"type":20},150,"3 Years","This study aims to explore lymph node metastasis in the short gastric mesentery following total gastrectomy with D2 lymphadenectomy plus complete mesogastric excision, providing evidence-based medicine for standardizing lymph node dissection in gastric cancer.",[28],[35,117,118,119,120],"Lymph node dissection","Short gastric mesentery","Lymph node metastasis","Tumor location","2025-08-25",{"date":123,"type":46},"2025-09-02",{"date":125,"type":46},"2024-05-01",{"date":127,"type":20},"2027-12-31",{"name":129,"class":100},"Jichao Qin",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":137,"enrollmentInfo":138,"targetDuration":4,"studyType":21,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":146,"completionDateStruct":148,"leadSponsor":150,"locationsCount":101},"100584906","phase-2-robotic-gastrectomy-for-locally-advanced-gastric-cancer-after-neoadjuvant-therapy-100584906","NCT06895447","Robotic Gastrectomy for Locally Advanced Gastric Cancer After Neoadjuvant Therapy","Efficacy and Safety of Robotic Radical Gastrectomy in Patients With Locally Advanced Gastric Cancer After Neoadjuvant Therapy","Inclusion Criteria:\n\n* Aged 18 to 80 years, regardless of gender.\n* Histologically confirmed gastric cancer or gastroesophageal junction (GEJ) cancer that has received neoadjuvant therapy, with pathology confirming it is predominantly adenocarcinoma. For GEJ cancer, only Siewert Type III and Siewert Type II cases that do not require combined thoracotomy are eligible.\n* Tumor stage confirmed as cStage III, suitable for curative R0 resection, as determined by an evaluation by a gastrointestinal surgeon and a radiologic technician prior to enrollment. The patient agrees to undergo robotic-assisted radical surgery, and the surgeon judges there are no surgical contraindications.\n* Expected survival of ≥6 months.\n* Measurable tumor lesions as defined by RECIST v1.1 criteria (see Attachment 1).\n* Preoperative ECOG performance status score (see Attachment 2) of 0 or 1.\n* Good cardiac function, capable of undergoing a curative resection. If there are clinical indications, patients with underlying ischemic, valvular heart disease, or other serious heart conditions should undergo preoperative assessment by a cardiologist.\n* Normal major organ function, with the following laboratory criteria:\n* Absolute neutrophil count (ANC) ≥ 1.2 x 10\\^9\u002FL in the absence of granulocyte colony-stimulating factor use within the past 14 days.\n* Platelet count ≥ 100 x 10\\^9\u002FL in the absence of blood transfusion within the past 14 days.\n* Hemoglobin \\> 8 g\u002FdL in the absence of blood transfusion or erythropoietin use within the past 14 days.\n* Total bilirubin ≤ 1.5 × the upper limit of normal (ULN); if total bilirubin \\> 1.5 × ULN but direct bilirubin ≤ ULN, inclusion is permitted.\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN.\n* Serum creatinine ≤ 1.5 × ULN and creatinine clearance (calculated by the Cockcroft-Gault formula) ≥ 60 mL\u002Fmin.\n* Coagulation function defined by international normalized ratio (INR) or prothrombin time (PT) ≤ 1.5 × ULN.\n* Normal thyroid function, defined by thyroid-stimulating hormone (TSH) within the normal range. If baseline TSH is outside the normal range, patients with normal total T3 (or FT3) and FT4 levels may still be eligible.\n* Normal range for myocardial enzyme profile (patients with isolated laboratory abnormalities deemed clinically insignificant by the investigator may still be included).\n* Thyroid function tests (TSH, FT3\u002FFT4) within normal limits or with minor clinically insignificant abnormalities.\n* Weight ≥ 40 kg (inclusive) or BMI \\> 18.5.\n* The participant has read, understood, and signed the informed consent form.\n\nExclusion Criteria:\n\n* Patients with a history of (within the past 5 years) or current active malignancies. However, patients with cured localized tumors, such as basal cell carcinoma, squamous cell carcinoma, superficial bladder cancer, in situ prostate cancer, in situ cervical cancer, in situ breast cancer, stage I lung cancer, stage I colorectal cancer, etc., are eligible.\n* A history of upper abdominal surgery (except for laparoscopic cholecystectomy).\n* A history of gastric resection, endoscopic mucosal resection (EMR), or endoscopic submucosal dissection (ESD).\n* Patients requiring surgery for other diseases concurrently.\n* Emergency surgery performed due to complications of gastric cancer (e.g., bleeding, obstruction, or perforation).\n* Patients preparing for or with a history of organ or bone marrow transplantation.\n* Blood transfusion within 2 weeks prior to surgery or a history of bleeding disorders, or any severe bleeding event (grade 3 or above according to CTCAE 4.0) occurring within 4 weeks prior to surgery.\n* Coagulation disorders or bleeding tendencies (INR \\> 1.5 without anticoagulant use); patients receiving anticoagulants or vitamin K antagonists, such as warfarin, heparin, or similar agents. Low-dose warfarin (1 mg oral daily) or low-dose aspirin (≤100 mg daily) may be allowed for preventive purposes, provided the prothrombin time international normalized ratio (INR) is ≤ 1.5.\n* History of thromboembolic events (e.g., stroke, transient ischemic attack, deep vein thrombosis, pulmonary embolism) within 6 months prior to screening. Patients with venous thrombosis caused by prior chemotherapy and deemed healed by the investigator are excluded.\n* Myocardial infarction, poorly controlled arrhythmias (including QTc interval \\> 450 ms for males and \\> 470 ms for females) within 6 months prior to surgery. QTc interval should be calculated using the Fridericia formula.\n* NYHA class III or IV heart failure, or left ventricular ejection fraction (LVEF) \\\u003C 50% as per echocardiogram.\n* Pulmonary dysfunction with FEV1 \\\u003C 50% of predicted value.\n* Urinary protein ≥++ on routine urinalysis, confirmed by 24-hour urinary protein quantification \\> 1.0 g.\n* Clinically symptomatic pleural effusion or ascites requiring clinical intervention.\n* Human immunodeficiency virus (HIV) infection.\n* Active pulmonary tuberculosis.\n* Chronic non-healing wounds or fractures with incomplete healing.\n* History of interstitial lung disease, pneumoconiosis, radiation-induced pneumonitis, drug-induced pneumonitis, or severe pulmonary dysfunction that may interfere with the detection or management of potential drug-related pulmonary toxicity.\n* Known active or suspected autoimmune diseases, except those in stable condition at enrollment and without the need for systemic immunosuppressive therapy.\n* Severe chronic autoimmune diseases, such as systemic lupus erythematosus, inflammatory bowel diseases (e.g., ulcerative colitis, Crohn's disease), chronic diarrhea syndromes (e.g., irritable bowel syndrome), sarcoidosis, or tuberculosis. Active hepatitis B or C or HIV infections. Non-severe autoimmune conditions, such as controlled psoriasis, dermatitis, or arthritis, are eligible. Patients with hepatitis B virus (HBV) with a viral load \\\u003C 500 copies\u002Fml may be included.\n* Patients who require systemic corticosteroid treatment (\\> 10 mg\u002Fday prednisone equivalent) or other immunosuppressive drugs within 14 days prior to surgery or during the study period. However, the following are allowed for inclusion: patients without active autoimmune diseases may use topical or inhaled steroids or adrenal hormone replacement therapy with a dose ≤ 10 mg\u002Fday prednisone equivalent.\n* Patients who have an active infection requiring systemic antibiotic treatment within 14 days prior to surgery (excluding those receiving prophylactic antibiotics for conditions like urinary tract infections or chronic obstructive pulmonary disease).\n* Patients who have received live vaccines within 28 days prior to surgery; seasonal influenza vaccination with inactivated viral vaccines is excluded.\n* Patients currently enrolled in another clinical trial involving surgery-related treatments.\n* Patients with a history of alcoholism, drug abuse, or substance misuse. Patients who have stopped drinking alcohol are eligible.\n* Patients who do not comply with medical instructions, fail to follow prescribed medication regimens, or have incomplete data that could impact the assessment of efficacy or safety.\n* Pregnant or breastfeeding female patients.\n* Patients with conditions that may increase the risks of participating in the study or with other severe, acute, or chronic diseases deemed by the investigator to be unsuitable for participation.\n* Other situations determined by the investigator that make the patient unsuitable for this clinical trial.","80 Years",{"count":139,"type":20},40,[23],"This study is a prospective, open-label, single-arm phase II clinical trial designed to evaluate the safety and efficacy of robotic radical gastrectomy in patients with locally advanced gastric adenocarcinoma after undergoing neoadjuvant therapy. Conducted at multiple centers, the study aims to include 40 patients confirmed via histopathological and\u002For cytological analysis. Eligible participants must have stage III resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma based on imaging studies such as ultrasound endoscopy, CT, or MRI.\n\nPatients will receive 3-4 cycles of neoadjuvant therapy, followed by imaging evaluations to assess the treatment response and determine eligibility for radical D2 gastrectomy. Within 2-6 weeks of the final neoadjuvant treatment cycle, eligible patients will undergo robotic radical gastrectomy. Key outcomes include post-surgical complications, pathological responses (pCR, MPR, TRG), and objective response rates (ORR), alongside disease-free survival (DFS) and overall survival (OS).",[28],"2025-06-29",{"date":145,"type":46},"2025-07-01",{"date":147,"type":46},"2024-11-14",{"date":149,"type":20},"2028-12-30",{"name":151,"class":100},"The First Affiliated Hospital with Nanjing Medical University",{"id":153,"slug":154,"hasResults":11,"nctId":155,"briefTitle":156,"officialTitle":157,"acronym":4,"eligibilityCriteria":158,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":160,"targetDuration":4,"studyType":21,"phases":162,"briefSummary":163,"conditions":164,"keywords":4,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":101},"100574978","phase-1-ql1706-combined-with-sox-used-in-theperioperative-treatment-100574978","NCT06766305","QL1706 Combined With SOX Used in Theperioperative Treatment","Phase Ib\u002FII Clinical Study of QL1706 Combined With SOX Perioperative Treatment for Resectable Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Sign a written informed consent to join the study voluntarily;\n2. Histologically or cytologically confirmed adenocarcinoma of the stomach or gastroesophageal junction;\n3. Adenocarcinoma of the stomach or gastroesophageal junction was evaluated by CT\u002FMRI (primary clinical stage ≥T3 or N+, M0, according to AJCC 8th edition staging), including Siewert type II and III tumors\n4. Age 18-75 years old, male or female;\n5. ECOG PS 0-1 ;\n6. Have not received any anti-tumor treatment for gastric or gastroesophageal junction adenocarcinoma, including radiotherapy, chemotherapy, surgery, etc.;\n7. Surgical treatment is planned after the completion of neoadjuvant therapy, and R0 resection is expected;\n8. Expected survival ≥6 months;\n9. Normal functioning of major organs, including:\n\n   1. Blood routine examination (no blood component, cell growth factor are allowed within 7 days before the first use of the study drug) :\n\n      neutrophil count ≥ 1.5×109\u002FL Platelet count ≥ 80×109\u002FL Hemoglobin ≥ 80 g\u002FL\n   2. Blood biochemical examination:\n\n      Total bilirubin ≤ 1.5 x ULN ALT ≤ 2.5 x ULN, AST ≤ 2.5 x ULN, Serum creatinine ≤ 1.5×ULN, or creatinine clearance ≥ 50 mL\u002Fmin (Cocheroft-Gault formula)\n   3. Coagulation function:\n\n   International Standardized ratio (INR) ≤ 1.5 x ULN Activated partial thromboplastin time (APTT) ≤ 1.5 x ULN\n10. Fertile female subjects are required to take a serum or urine pregnancy test that is negative within 72 hours prior to the start of the study drug administration, and to use effective contraception (such as Iuds, contraceptives, or condoms) during the trial period and for at least 120 days after the last dose; For male subjects whose partner is a fertile woman, they should be surgically sterilized or agree to use effective contraception during the trial and for 120 days after the last dose;\n11. The subject have good compliance and cooperated well with the follow-up\n12. Agreed to provide tumor tissue samples\n\nExclusion Criteria:\n\n1. There are unresectable factors, including unresectable tumor causes or unresectable or refused surgery contraindications;\n2. Have received or are receiving any of the following treatment:\n\n   1. any radiation therapy, chemotherapy, or immune checkpoint inhibitors (such as anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.) and other anti-tumor drugs;\n   2. being treated with immunosuppressive drugs or systemic hormones for immunosuppressive purposes within 2 weeks prior to the initial use of the investigational drug (dose \\>10mg\u002F day prednisone or equivalent); In the absence of active autoimmune disease, inhaled or topical steroid use and adrenocortical hormone replacement with doses \\>10mg\u002F day of prednisone or equivalent are permitted;\n   3. Received live attenuated vaccine within 4 weeks prior to the first use of the investigational drug; If enrolled, subjects must not receive live vaccine during the study period or within 120 days after the last administration of QL1706;\n3. Serious infections (CTCAE \\> Grade 2) occurred within 4 weeks prior to the first use of the study drug, such as severe pneumonia, bacteremia, and infection complications requiring hospitalization; Baseline chest imaging indicated active pulmonary inflammation, signs and symptoms of infection within 14 days prior to the first use of the study drug, or the need for oral or intravenous antibiotic treatment, except in cases of prophylactic antibiotic use;\n4. Patients with active autoimmune disease requiring systemic treatment within 2 years prior to initial use of the investigational drug or a history of autoimmune disease with recurrence possible \\[including but not limited to autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, pituitaritis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (which can be controlled by hormone replacement therapy alone) Patients can be enrolled)\\];\n5. A history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation;\n6. There are clinical symptoms or diseases of heart that are not well controlled, including but not limited to: (1) NYHA grade II or above heart failure, (2) unstable angina pectoris, (3) myocardial infarction within 1 year, (4) Clinically significant supraventricular or ventricular arrhythmias that are not well controlled without or after clinical intervention; (5) QTc\\> 450ms (male); QTc \\> 470ms (female);\n7. Patients found to have active pulmonary tuberculosis infection through medical history or CT examination, or had a history of active pulmonary tuberculosis infection within 1 year before enrollment, or had a history of active pulmonary tuberculosis infection more than 1 year ago without formal treatment;\n8. There are factors that increase the risk of prolonged QTc and abnormal heart rate, such as heart failure, hypokalemia, congenital long QT syndrome, family history of long QT syndrome, sudden unexplained death of immediate family members under 40 years of age, or prolonged QT interval accompanied by medication;\n9. Active hepatitis (Hepatitis B reference: HBsAg positive and HBV DNA≥2000 IU\u002Fml; Hepatitis C reference: HCV antibody positive and HCV copy number \\> upper limit of normal);\n10. Defined as ≥ grade 2 peripheral neuropathy according to NCI-CTCAE v5.0 standards;\n11. Have been diagnosed with other malignancies within 5 years prior to initial dosing, unless malignancies with a low risk of metastasis or death (5-year survival \\> 90%), such as well-treated basal cell or squamous cell skin cancer of the skin or cervical carcinoma in situ may be considered for inclusion;\n12. Known history of severe hypersensitivity to other monoclonal antibodies; Patients with a known history of allergy or hypersensitivity to QL1706, oxaliplatin, and Tigor or any of their components;\n13. Known deficiency of dihydropyrimidine dehydrogenase;\n14. Upper gastrointestinal obstruction or abnormal physiological function or malabsorption syndrome that may affect the absorption of Tegor;\n15. Pregnant or lactating women;\n16. Enrolling in another clinical study at the same time, unless it is an observational, non-interventional clinical study or the follow-up period of an interventional study;\n17. The investigator determined that there were other factors that might have led to the forced termination of the study, such as other serious medical conditions (including mental illness) requiring co-treatment, alcohol, substance abuse, family or social factors, and factors that might have affected the safety or adhere","75 Years",{"count":161,"type":20},54,[65,23],"This is a single-center, single-arm clinical study to evaluate the efficacy and safety of QL1706 combined with SOX for the treatment of resectable locally advanced gastric or gastroesophageal junction adenocarcinoma.\n\nThe study consists of the following two phases:\n\nPhase 1: The safety introduction phase of QL1706 combined with SOX, using a 3+3 design, enrolled about 6 to 12 patients with locally advanced gastric\u002Fgastroesophageal junction adenocarcinoma (primary clinical stage ≥T3 or N+, M0) and underwent 3-week DLT evaluation.\n\nPhase 2: This phase plans to enroll 42 to 45 patients, using investigator-evaluated pCR as the primary endpoint. QL1706 is administered by intravenous infusion of RP2D as defined in Part 1 starting from cycle 1.\n\nPreoperative QL1706 RP2D combined with SOX (3 cycles) → radical surgery (D2) → postoperative QL1706 RP2D combined with SOX (5 cycles) → postoperative maintenance of QL1706 RP2D (up to 1 year before and after surgery); neoadjuvant therapy Surgery should be performed within 3 to 6 weeks after the last dosing, with a minimum interval of 4 weeks after surgery and a maximum interval of 6 weeks recommended for postoperative adjuvant therapy.",[28,165],"Esophagogastric Junction Cancers","2025-06-12",{"date":168,"type":46},"2025-06-17",{"date":170,"type":46},"2025-03-21",{"date":172,"type":20},"2031-06-30",{"name":174,"class":100},"Xiangdong Cheng",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":159,"enrollmentInfo":183,"targetDuration":4,"studyType":88,"phases":4,"briefSummary":185,"conditions":186,"keywords":187,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":191,"lastUpdatePostDateStruct":192,"startDateStruct":194,"completionDateStruct":196,"leadSponsor":198,"locationsCount":101},"100593199","correlation-of-psychological-distress-and-immune-checkpoint-inhibitors-in-gastric-cancer-100593199","NCT07003334","Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric Cancer","Correlation of Psychological Distress With Efficacy of Immune Checkpoint Inhibitors in Patients With Advanced Gastric Cancer","PDICI","Inclusion Criteria:\n\n* Voluntary signing of informed consent;\n* 18≦ age ≦75 years;\n* Sex: no limitation;\n* Patients with gastric adenocarcinoma diagnosed according to the 15th edition of the Japanese gastric cancer statute, 2017, after endoscopic biopsy of the primary lesion;\n* Patients requiring preoperative immune checkpoint inhibitor therapy at the discretion of the treating physician, followed by radical gastrectomy.\n\nExclusion Criteria:\n\n* Women who are pregnant or breastfeeding;\n* Serious mental illness;\n* History of upper abdominal surgery (except for laparoscopic cholecystectomy) ;\n* Patients with gastric cancer who do not wish to undergo neoadjuvant immunotherapy;\n* Patients with a history of continuous systemic corticosteroid therapy within the past 1 month;\n* Patients with active infection, active or refractory autoimmune disease, or uncontrolled systemic disease;\n* Patients at the discretion of the investigator, were deemed unsuitable for participation in this study.",{"count":184,"type":20},268,"1. Background Gastric cancer (GC) is a leading global cause of cancer-related mortality, with over 1 million new cases and 769,000 deaths in 2020. In China, 80% of patients present with advanced disease, for whom perioperative chemotherapy, surgery, and lymphadenectomy are standard. Recent phase III trials (Checkmate-649, KEYNOTE-062, ORIENT-16) demonstrate that immune checkpoint inhibitors (ICIs) combined with chemotherapy improve progression-free survival (PFS: 2.8-10.5 months) and overall survival (OS: 11.1-18.4 months) compared to chemotherapy alone. However, outcomes remain suboptimal, necessitating exploration of novel predictive biomarkers and resistance mechanisms.\n\n   Emerging evidence implicates chronic stress in cancer progression and treatment response. Chronic stress activates the hypothalamic-pituitary-adrenal (HPA) axis and sympathetic nervous system, elevating cortisol, catecholamines, and glucocorticoids. These hormones suppress immune function by reducing CD8+ T cells and natural killer (NK) cell activity while increasing immunosuppressive cells (e.g., regulatory T cells, myeloid-derived suppressor cells). Preclinical studies link chronic stress to metastasis via extracellular trap (NET) formation, impaired antitumor immunity, and resistance to PD-1\u002FPD-L1 blockade. Clinically, chronic stress correlates with worse survival in non-small-cell lung cancer patients receiving ICIs. Despite these findings, psychological screening remains underutilized in oncology. This study aims to investigate the impact of chronic stress on ICI efficacy in advanced gastric cancer.\n2. Objectives\n\n   Primary Objective:\n\n   Evaluate the association between chronic stress and tumor response (via Tumor Regression Grade, TRG) in advanced gastric cancer patients undergoing neoadjuvant immunotherapy.\n\n   Secondary Objectives:\n\n   Assess the effect of chronic stress on post-gastrectomy quality of life (QoL).\n\n   Analyze correlations between chronic stress biomarkers and survival outcomes (PFS, OS).\n3. Study Endpoints\n\n   Primary Endpoint:\n\n   Pathological response assessed by TRG (Mandard criteria).\n\n   Secondary Endpoints:\n\n   QoL (EORTC QLQ-C30\u002FSTO22 questionnaires).\n\n   PFS and OS.\n\n   Exploratory Endpoints:\n\n   Dynamic changes in chronic stress biomarkers (serum cortisol, ACTH, epinephrine, norepinephrine, serotonin).\n\n   Correlation of biomarker levels with TRG and survival.\n4. Study Design Type: Single-center, prospective observational study. Duration: 36 months. Sample Size: 268 patients (134 high chronic stress, 134 low chronic stress).\n\n   Inclusion Criteria:\n\n   Age 18-75 years.\n\n   Histologically confirmed gastric adenocarcinoma (per Japanese Gastric Cancer Guidelines, 2017).\n\n   Scheduled for neoadjuvant immunotherapy + radical gastrectomy.\n\n   Informed consent.\n\n   Exclusion Criteria:\n\n   Pregnancy\u002Fbreastfeeding.\n\n   Prior upper abdominal surgery (excluding cholecystectomy).\n\n   Active infection, autoimmune disease, or corticosteroid use within 1 month.\n\n   Psychiatric disorders or investigator-deemed unsuitability.\n\n   Withdrawal Criteria:\n\n   Patient request, loss to follow-up, or safety concerns.\n5. Methods\n\n   Chronic Stress Assessment:\n\n   Validated psychological questionnaires (e.g., Hospital Anxiety and Depression Scale) at baseline and treatment milestones.\n\n   Biomarker analysis: Serum cortisol, ACTH, epinephrine, norepinephrine, serotonin at key timepoints (pre-treatment, post-neoadjuvant therapy, post-surgery).\n\n   Clinical Data Collection:\n\n   TRG evaluation post-surgery.\n\n   QoL assessments at 1, 3, 6, 12, 18, 24, and 36 months post-surgery.\n\n   Survival tracking via hospital records and follow-up visits.\n\n   Statistical Analysis:\n\n   Stratification by baseline stress scores (high\u002Flow).\n\n   Cox regression for survival outcomes; logistic regression for TRG-QoL correlations.\n\n   Significance threshold: \\*p\\* \\\u003C 0.05.\n6. Significance This study addresses a critical gap in understanding how psychological factors modulate ICI efficacy. By identifying chronic stress as a predictor of treatment response, results may guide personalized interventions (e.g., beta-blockers, behavioral therapy) to improve outcomes in advanced gastric cancer.",[28],[188,189,190],"Psychological Distress","Immune Checkpoint Inhibitors","Gastric Cancer","2025-05-26",{"date":193,"type":46},"2025-06-04",{"date":195,"type":46},"2025-01-03",{"date":197,"type":20},"2026-12-31",{"name":199,"class":100},"Nanfang Hospital, Southern Medical University",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":4,"eligibilityCriteria":206,"healthyVolunteers":207,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":208,"targetDuration":210,"studyType":88,"phases":4,"briefSummary":211,"conditions":212,"keywords":229,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":237,"lastUpdatePostDateStruct":238,"startDateStruct":240,"completionDateStruct":242,"leadSponsor":244,"locationsCount":246},"100579293","raman-spectroscopy-based-deep-learning-model-for-early-pan-cancer-early-diagnosis-100579293","NCT06822413","Raman Spectroscopy-Based Deep Learning Model for Early Pan-Cancer Early Diagnosis","A Novel Raman Spectroscopy-Based Method for Pan-Cancers Early Diagnosis Supported by Deep Learning: A Prospective, Single-Arm, Multicentre Study","Inclusion Criteria:\n\n* Histopathological diagnosis of malignant tumors, including colorectal cancer, gastric cancer, hepatic cancer, pancreatic cancer, and esophageal cancer.\n* Patients in normal physiological conditions without any malignant tumors or precancerous lesions.\n* Patients with malignant tumor without recieving any interventions, including chemotherapy, surgery, radiotherapy, immunotherapy or other anti-tumor treatments.\n* Patients with a histopathological diagnosis of any precancerous lesions or non-malignant disease.\n\nExclusion Criteria:\n\n* Patients with metastatic tumors or in the condition with two or more kinds of malignant tumors at the same time\n* Post-cancer treatment patients.",true,{"count":209,"type":20},600,"1 Year","The goal of this observational study is to explore whether a Raman-based, deep learning-assisted approach can be used to develop an effective method for early pan-cancer screening. The study includes healthy individuals, patients at risk of cancer, and patients with diagnosed cancers. The main questions it aims to answer are:\n\n* Evaluating the deep-learning model's accuracy and specificity in identifying cancer-specific features in Raman spectral data and determining whether this method can accurately classify patients based on risk.\n* Identifying which model is more adaptable to the Raman spectrum\n* Providing an interpretable analysis of the model-generated diagnosis Participants are already being diagnosed and follow-up to determine the type of cancer.",[213,214,215,216,28,217,218,219,220,221,222,223,224,225,226,227,228],"Cancer Diagnosis","Liver Cancer, Adult","Cancer Screening","Colorectal Cancer (CRC)","Normal Physiology","Pancreatic Cancer, Adult","Raman Spectroscopy","Deep Learning Model","Esophageal Cancer","Malignant Tumours","Precancerous Conditions","Pancreatitis","Adenoma Colon Polyp","Gastric Ulcer","Oesophagitis","Cirrhoses, Liver",[230,231,215,219,27,68,190,221,232,233,224,234,235,227,236],"Pan-cancer","Deep Learning Models","malignant tumour","Precancerous Condtions","Colorectal Adenoma","Gastirc Ulcer","Cirrhoses","2025-04-19",{"date":239,"type":46},"2025-04-24",{"date":241,"type":46},"2022-09-01",{"date":243,"type":20},"2025-07-28",{"name":245,"class":100},"Second Affiliated Hospital, School of Medicine, Zhejiang University",4,{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":207,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":21,"phases":256,"briefSummary":258,"conditions":259,"keywords":264,"overallStatus":42,"whyStopped":4,"lastUpdateSubmitDate":269,"lastUpdatePostDateStruct":270,"startDateStruct":272,"completionDateStruct":273,"leadSponsor":275,"locationsCount":101},"100564723","ai-assisted-non-contrast-ct-for-multi-cancer-screening-100564723","NCT06632886","AI-Assisted Non-Contrast CT for Multi-Cancer Screening","A Prospective Cohort Study Evaluating the Utility of Artificial Intelligence-Assisted Non-Contrast Computed Tomography for Multi-Cancer Screening in Asymptomatic Individuals Undergoing Routine Health Examinations","Inclusion Criteria:\n\n1. Subject is able and willing to provide informed consent and sign an informed consent form.\n2. Subject has undergone an abdominal or chest non-contrast CT scan.\n\nExclusion Criteria:\n\n1. Subject has been diagnosed with one of the following cancers within the last five years: lung, liver, stomach, colon, esophageal, pancreatic, or breast cancer;\n2. Subject has any medical condition that contraindicates high-resolution MRI\u002FCT\u002FEndoscopy;\n3. Subject cannot be followed up or is participating in other clinical trials.",{"count":255,"type":20},1000000,[257],"NA","Cancer poses a major public health challenge in China. Early detection can improve treatment outcomes and survival rates. In this study, we will conduct a large-scale, prospective, multi-center cohort study to evaluate the utility of AI-assisted non-contrast CT for multi-cancer screening.\n\nThe study aims to enroll 1 million asymptomatic participants undergoing routine health examinations, using an AI imaging model based on non-contrast CT to detect seven cancers such as lung, liver, gastric, colorectal, esophageal, pancreatic, and breast cancers. Positive cases will be required to be referred to Shanghai Changhai Hospital for further imaging and care based on National Comprehensive Cancer Network (NCCN) and American College of Radiology (ACR) guidelines. The goal is to assess the AI model's diagnostic performance for seven cancer types, especially for early-stage, resectable tumors.",[260,261,28,262,221,68,263],"Lung Cancers","Liver Cancer","Colorectal, Cancer","Breast Cancer",[265,266,267,268],"Screening","Early Diagnosis","Artificial Intelligence","Cancer","2024-10-07",{"date":271,"type":46},"2024-10-09",{"date":269,"type":20},{"date":274,"type":20},"2027-10-07",{"name":276,"class":100},"Guo ShiWei"]